Verity announces a licensing agreement for Mitomycin with Vygoris, UK.

Toronto, Ontario (November 1, 2018) — Verity Pharmaceuticals Inc. is pleased to announce an exclusive Canadian licensing and supply agreement with Vygoris Ltd., London, UK, for the supply of Mitomycin to the Canadian pharmaceutical market.

Under the terms of the exclusive agreement, Vygoris will supply the finished product and Verity will market and distribute. Mitomycin is a cancer-fighting medication used primarily to treat bladder cancer as well as some types of colon and stomach cancer.


A reliable supply and therapeutic option that physicians need

“In recent years, Mitomycin has undergone drug shortages across Canada and has caused considerable concern for patients undergoing bladder cancer treatment. Being able to offer a safe and reliable supply of Mitomycin aligns with our commitment to bringing therapeutically relevant and required products to the Canadian healthcare community. ” – Howard Glase, CEO Verity Pharma


A proven standard of care

Approved in the early 1960s and used in more than 80 countries worldwide, Mitomycin belongs to the group of cancer-fighting medications known as antineoplastics, and specifically to the group of antineoplastics called actinomycins. It kills cancer cells by interfering with their growth and reproduction and can be used alone or in combination with other antineoplastic medications, radiation, or surgery.

“Although Mitomycin is currently indicated in Canada to treat transitional cell bladder cancer as well as certain types of stomach and colon cancers, it has also been used in the treatment of anal, breast, cervical, vulvar, colorectal, pancreatic, head and neck, and non-small cell lung cancer. It offers physicians a proven therapeutic option when determining the best treatment for their patients.” – Dr. Neil Fleshner MD, MPH, FRCSC, Chairman of Urology at University of Toronto, Chief Medical Officer, Verity Scientific Advisory Board


About Vygoris

Located in the UK, Vygoris is a newly formed subsidiary of the French specialist generics company Substipharm. Its focus is on specialized pharmaceutical products. “This deal is a key milestone for us in our international development strategy. Our team is continuously looking for the next opportunity, the next idea, the next development that can improve our existing products. That includes working hard with the best partners both at home and internationally and Verity Pharma’s similar position in the Canadian healthcare market makes them a perfect fit.” – Philippe Beaupere, Managing Director, Vygoris UK


About Verity Pharmaceuticals

Verity Pharma is a specialty pharmaceutical company focused on providing therapeutically relevant legacy agents to the Canadian healthcare community. Introducing a new source of Mitomycin to Canada is another initiative that fulfills our mandate to ensure access to prescription products that have been withdrawn from the market, are in short supply, or have not yet been made available in this country.